Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.
Ahmad, Abrar LU ; Sundquist, Kristina LU ; Zöller, Bengt LU
; Svensson, Peter
LU
; Sundquist, Jan
LU
and Memon, Ashfaque
LU
(2016)
In Journal of Thrombosis and Thrombolysis
42(1).
p.135-141
- Abstract
- Thrombomodulin gene (THBD) is a critical cofactor in protein C anticoagulant system. THBD c.1418C>T polymorphism is reported to be associated with higher risk of primary venous thromboembolism (VTE) but its role in VTE recurrence is unknown. The aim of this study was to investigate the role of THBD polymorphism in VTE recurrence. THBD c.1418C>T polymorphism was genotyped by using Taqman polymerase chain reaction in a prospective population based study of 1465 consecutive objectively verified VTE patients. Uni- and multivariate Cox regression were performed for the risk assessment of VTE recurrence. Patients who had VTE before inclusion or had recurrence or died during anticoagulant treatment were excluded. Among the remaining (N =... (More)
- Thrombomodulin gene (THBD) is a critical cofactor in protein C anticoagulant system. THBD c.1418C>T polymorphism is reported to be associated with higher risk of primary venous thromboembolism (VTE) but its role in VTE recurrence is unknown. The aim of this study was to investigate the role of THBD polymorphism in VTE recurrence. THBD c.1418C>T polymorphism was genotyped by using Taqman polymerase chain reaction in a prospective population based study of 1465 consecutive objectively verified VTE patients. Uni- and multivariate Cox regression were performed for the risk assessment of VTE recurrence. Patients who had VTE before inclusion or had recurrence or died during anticoagulant treatment were excluded. Among the remaining (N = 1046) patients, 126 (12.05 %) had VTE recurrence during the follow up period (from 1998 to 2008). THBD polymorphism was not significantly associated with risk of VTE recurrence in the univariate [Hazard ratio (HR) 1.11, 95 % confidence interval (CI) 0.78-1.59, p = 0.55] as well as the multivariate analysis adjusted for age, sex and thrombophilia (HR 1.11, 95 % CI 0.78-1.59, p = 0.54). Similarly, in unprovoked first VTE (n = 614), no association was observed between THBD polymorphism and risk of VTE recurrence (HR 1.22 and 95 % CI 0.78-1.89, p = 0.38). In this prospective study, our results do not suggest a predictive role for THBD c.1418C>T polymorphism in VTE recurrence. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8592772
- author
- Ahmad, Abrar
LU
; Sundquist, Kristina
LU
; Zöller, Bengt
LU
; Svensson, Peter
LU
; Sundquist, Jan
LU
and Memon, Ashfaque
LU
- organization
- publishing date
- 2016-01-07
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Thrombosis and Thrombolysis
- volume
- 42
- issue
- 1
- pages
- 135 - 141
- publisher
- Springer
- external identifiers
-
- pmid:26743062
- scopus:84953396647
- pmid:26743062
- wos:000376644500018
- ISSN
- 1573-742X
- DOI
- 10.1007/s11239-015-1328-x
- project
- Identification of diagnostic and prognostic biomarkers of venous thromboembolism and its recurrence
- Genetic risk factor of venous thromboembolism and its recurrence
- language
- English
- LU publication?
- yes
- id
- 2a11cfbb-a17b-46de-b719-3a83ceffb2ee (old id 8592772)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26743062?dopt=Abstract
- date added to LUP
- 2016-04-04 09:23:27
- date last changed
- 2022-04-23 20:18:31
@article{2a11cfbb-a17b-46de-b719-3a83ceffb2ee,
abstract = {{Thrombomodulin gene (THBD) is a critical cofactor in protein C anticoagulant system. THBD c.1418C>T polymorphism is reported to be associated with higher risk of primary venous thromboembolism (VTE) but its role in VTE recurrence is unknown. The aim of this study was to investigate the role of THBD polymorphism in VTE recurrence. THBD c.1418C>T polymorphism was genotyped by using Taqman polymerase chain reaction in a prospective population based study of 1465 consecutive objectively verified VTE patients. Uni- and multivariate Cox regression were performed for the risk assessment of VTE recurrence. Patients who had VTE before inclusion or had recurrence or died during anticoagulant treatment were excluded. Among the remaining (N = 1046) patients, 126 (12.05 %) had VTE recurrence during the follow up period (from 1998 to 2008). THBD polymorphism was not significantly associated with risk of VTE recurrence in the univariate [Hazard ratio (HR) 1.11, 95 % confidence interval (CI) 0.78-1.59, p = 0.55] as well as the multivariate analysis adjusted for age, sex and thrombophilia (HR 1.11, 95 % CI 0.78-1.59, p = 0.54). Similarly, in unprovoked first VTE (n = 614), no association was observed between THBD polymorphism and risk of VTE recurrence (HR 1.22 and 95 % CI 0.78-1.89, p = 0.38). In this prospective study, our results do not suggest a predictive role for THBD c.1418C>T polymorphism in VTE recurrence.}},
author = {{Ahmad, Abrar and Sundquist, Kristina and Zöller, Bengt and Svensson, Peter and Sundquist, Jan and Memon, Ashfaque}},
issn = {{1573-742X}},
language = {{eng}},
month = {{01}},
number = {{1}},
pages = {{135--141}},
publisher = {{Springer}},
series = {{Journal of Thrombosis and Thrombolysis}},
title = {{Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.}},
url = {{https://lup.lub.lu.se/search/files/11286550/5311704.pdf}},
doi = {{10.1007/s11239-015-1328-x}},
volume = {{42}},
year = {{2016}},
}